Welcome to our dedicated page for Aurora Cannabis news (Ticker: ACB), a resource for investors and traders seeking the latest updates and insights on Aurora Cannabis stock.
Aurora Cannabis Inc. (ACB) is a Canada-based global medical cannabis company with shares listed on NASDAQ and the Toronto Stock Exchange. From an investor and industry perspective, Aurora’s news flow centers on medical cannabis expansion, scientific research, international market development and operational performance.
Company announcements frequently highlight growth in global medical cannabis revenue, leadership positions in key markets, and updates on its plant propagation business through Bevo Farms Ltd. Earnings releases and financial updates provide detail on segment performance across medical cannabis, consumer cannabis and plant propagation, along with adjusted gross margins, adjusted EBITDA and working capital trends.
News items also cover Aurora’s international initiatives, such as investments in its EU-GMP manufacturing facility in Leuna, Germany, launches of proprietary medical flower cultivars in Poland under the Cannabis flos Aurora brand, and the introduction of the Daily Special medical brand in Germany. In Australia, updates include distribution partnerships through MedReleaf Australia and Leafio, aimed at expanding access to Aurora’s medical cannabis products via pharmacy networks.
Scientific and educational developments are another recurring theme. Aurora reports progress in powdery mildew resistance research (PM2) conducted at its Aurora Coast R&D facility, including breeding programs and production trials. The company also announces collaborations like the Physician Experience Platform (PEP) with Copeia, which provides anonymized, peer-reviewed medical cannabis case studies for physicians in multiple countries.
Investors following ACB news can expect coverage of quarterly results, international facility investments, product launches, distribution agreements, conference participation and medical education initiatives. Bookmark this page to monitor how Aurora’s strategic focus on global medical cannabis, science and international markets is reflected in its ongoing news and disclosures.
Summary not available.
Aurora Cannabis Inc. (NASDAQ: ACB, TSX: ACB) has announced the launch of a new tracking program to enhance the wellness journey of cannabis patients. Set to empower users alongside healthcare advice, the Strainprint® App allows users to record symptoms and consumption habits, helping them identify the most suitable cannabis strains and dosages. This initiative aligns with Aurora's commitment to improving patient lives through innovative solutions in the cannabis industry. The Strainprint App is available for free on both the Apple Store and Google Play Store. With a focus on quality and patient well-being, Aurora continues to advance in both medical and recreational cannabis sectors.
Aurora Cannabis (NASDAQ: ACB) announced an exciting new product lineup set to launch in April 2023, featuring original cultivars and strain-specific products aimed at both medical patients and recreational consumers. The new offerings include:
- Pink Diesel '71 and Moon Berry flower strains from Aurora's breeding program.
- Tangerine Dream Cured Resin Gummies infused with strain-specific cured resin.
- Slymer and Trufflez Live Resin Vapes.
The expansion aims to meet the increasing demand for high-quality cannabis products, leveraging Aurora's genetics and research capabilities. Vice President Lana Culley emphasizes a commitment to innovation and quality, aiming to resonate with both consumer expectations and market trends.
Aurora Cannabis has recently repurchased approximately $22.3 million of its convertible senior notes, with a total cash cost of $16.7 million. This strategic move is aimed at reducing debt and annual cash interest expenses, leading to expected savings of $2.6 million annually. Since December 2021, Aurora has repurchased a total of $385 million in notes, realizing annual cash interest savings of around $21 million. The company now holds approximately $79 million in outstanding notes, reinforcing its strong balance sheet, which is among the best in the Canadian cannabis sector. Aurora continues to focus on profitable growth in both the global medical and Canadian adult-use markets.
Aurora Cannabis (NASDAQ: ACB) and MedReleaf Australia have launched IndiMed Tempo 26, a new line of higher THC dried cannabis products for medical patients under the MedReleaf Concession Scheme (MCS). This initiative aims to enhance patient choice and accessibility to medical cannabis in Australia. Tempo 26 expands the product offerings available to doctors, allowing for more flexible prescriptions. The MCS provides discounted products for patients with certain concession cards, making it easier for those facing serious health conditions to access necessary treatments. Aurora holds a 10% stake in MedReleaf Australia, which is committed to high-quality cannabis cultivation.
Aurora Cannabis (ACB) has successfully repurchased approximately $46.6 million of its convertible senior notes for $45.6 million in cash, saving $2.6 million in annual interest payments. This repurchase, executed at a 2.5% discount to par value, is part of Aurora's strategy to enhance financial discipline and reduce debt. Since December 2021, the company has repurchased a total of $366 million in notes, leading to annual savings of $20 million. Aurora's balance sheet remains among the strongest in the Canadian cannabis sector, with a focus on profitable growth in medical and adult-use markets.
Aurora Cannabis Inc. (NASDAQ: ACB) received a notification letter from Nasdaq on March 24, 2023, indicating non-compliance with the Minimum Bid Price Requirement due to its share price closing below US$1.00 for 30 consecutive business days (from February 8 to March 23, 2023). The Company has until September 20, 2023, to regain compliance. If the share price closes at or above US$1.00 for ten consecutive business days, Nasdaq will notify that compliance has been achieved. This notification does not affect daily trading or listings on the Toronto Stock Exchange, and Aurora plans to monitor its share price to resolve this deficiency.
Aurora Cannabis Inc. (NASDAQ: ACB) announced the filing of a new preliminary short form base shelf prospectus with Canadian securities regulators, excluding Quebec, on March 17, 2023. This Base Shelf Prospectus aims to replace the existing one and will qualify the issuance of up to U.S. $650 million in various securities over a 25-month period. Approximately U.S. $412 million is allocated for the potential exercise of outstanding warrants, leaving about U.S. $238 million for new issuances. The release emphasizes that this announcement does not constitute an offer of securities for sale.
Aurora Cannabis Inc. (NASDAQ: ACB) has launched a new cannabis cultivar, Valour, specifically designed for veterans. This product, marketed under the MedReleaf brand, features genetics from Chemdawg, OG18, and Skunk, with THC levels ranging from 20-26%. Five percent of Valour's net profits will support veteran organizations across Canada, with a cap of $200,000 per year. Valour aims to meet veterans' needs by embodying their preferred traits in aroma and flavor. The initiative highlights Aurora's commitment to the veteran community and aims to foster significant contributions to organizations providing essential support to veterans.
Aurora Cannabis Inc. (NASDAQ: ACB, TSX: ACB) and MedReleaf Australia have launched CraftPlant, a new medical cannabis brand for Australian patients. This brand features three THC-dominant strains—Greendae, Navana, and HiVolt—developed from premium cultivars by Aurora's science division, Occo. The products are produced under strict EU-GMP guidelines and are available in 10g containers. Aurora holds a 10% stake in MedReleaf Australia and aims to enhance its presence in the promising Australian market. The partnership increases the total MedReleaf products available for Australian doctors to 27, offering diverse treatment solutions.